A month after a sickle cell pain crisis, columnist Dunstan Nicol-Wilson is learning how to trust his body again, which isn't easy.

The gene-editing therapy OTQ923 normalized brain blood flow in 3 sickle cell disease patients, suggesting it may lower stroke ...

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for sickle cell disease.